Literature DB >> 18685336

The high-risk donor: viral infections in solid organ transplantation.

Andrew L Singer1, Lauren M Kucirka, Ruth Namuyinga, Colleen Hanrahan, Aruna K Subramanian, Dorry L Segev.   

Abstract

PURPOSE OF REVIEW: Recently, four organ recipients were infected with HIV through transplantation, raising questions about current serologic testing policies. Currently, the decision to use enzyme-linked immunosorbent assay or nucleic acid testing, an expensive and time-consuming method capable of detecting more recent infections, is left up to individual organ procurement organizations. The purpose of this review was to present estimates of the window period between infection and detection by enzyme-linked immunosorbent assay and nucleic acid testing for HIV, hepatitis B virus, and hepatitis C virus; and to evaluate the impact of those infections on posttransplant outcomes. RECENT
FINDINGS: Nucleic acid testing for HIV can detect infections 12-13 days earlier than enzyme-linked immunosorbent assay; in the case of hepatitis B virus, infections are detected 21.8-36 days earlier; and in the case of hepatitis C virus, infections are detected 26-60 days earlier. Studies indicate that it is possible to manage all three infections posttransplant. HIV/hepatitis C virus coinfections seem to present the greatest posttransplant management challenges due to drug toxicities.
SUMMARY: Nucleic acid testing can reduce the window period and thus increase the probability of detecting viral infections. HIV, hepatitis B virus, and hepatitis C virus positive organs may be appropriate for use in some situations; nucleic acid testing helps patients and physicians make informed decisions about their use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685336     DOI: 10.1097/MOT.0b013e3283094ba3

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  9 in total

1.  Occult hepatitis B in blood donors: a description of two cases.

Authors:  Ciro Capezzuto; Eva Franchi; Simona Urbani; Luisa Romanò; Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

2.  Outcomes After Declining Increased Infectious Risk Kidney Offers for Pediatric Candidates in the United States.

Authors:  Mary G Bowring; Kyle R Jackson; Heather Wasik; Alicia Neu; Jacqueline Garonzik-Wang; Christine Durand; Niraj Desai; Allan B Massie; Dorry L Segev
Journal:  Transplantation       Date:  2019-12       Impact factor: 4.939

3.  Prevalence of antibodies to hepatitis C virus in voluntary blood donors: are women better donors?

Authors:  Dakshayani Padmakar Pandit; Pradhan Pagaro M; Chaudhury Nabamita
Journal:  J Clin Diagn Res       Date:  2014-04-15

Review 4.  Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-02       Impact factor: 8.086

Review 5.  Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

6.  Turn down for what? Patient outcomes associated with declining increased infectious risk kidneys.

Authors:  Mary G Bowring; Courtenay M Holscher; Sheng Zhou; Allan B Massie; Jacqueline Garonzik-Wang; Lauren M Kucirka; Sommer E Gentry; Dorry L Segev
Journal:  Am J Transplant       Date:  2017-12-05       Impact factor: 8.086

7.  Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Authors:  Ingo Schmack; Seda Ballikaya; Brigitte Erber; Irina Voehringer; Ulrich Burkhardt; Gerd U Auffarth; Paul Schnitzler
Journal:  Transfus Med Hemother       Date:  2019-09-24       Impact factor: 3.747

Review 8.  Evaluating the risk of transmission of infection from donor to recipient of a solid organ transplantation.

Authors:  Óscar Len; Antonio Ramos; Albert Pahissa
Journal:  Enferm Infecc Microbiol Clin       Date:  2012-03       Impact factor: 1.731

9.  New tools in HCV diagnosis, in light of the enhanced awareness and the new drugs for treatment: SMARTube and stimmunology.

Authors:  Svetlana Gorodin; Serhat Unal; Youchun Wang; Mikhail I Mikhaylov; Ludmila Bigbulatova; Tamar Jehuda-Cohen
Journal:  ScientificWorldJournal       Date:  2013-02-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.